Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22574188 | 0.87 | HTT (0.72) | MEN1KMT2AKDRHTTALDH1A1 | |
| SCHEMBL22574239 | 0.86 | LMNA (0.69) | MEN1KMT2ANAMPTHTTALDH1A1 | |
| SCHEMBL22574023 | 0.86 | MEN1 (0.66) | MEN1KMT2AHTTALDH1A1ROCK2 | |
| SCHEMBL22574154 | 0.84 | CYP11B1 (0.60) | MEN1KMT2AKDRHTTALDH1A1 | |
| SCHEMBL485711 | 0.84 | MEN1 (0.82) | MEN1KMT2AKDRHTTALDH1A1 | |
| SCHEMBL22574392 | 0.84 | MEN1 (0.59) | MEN1KMT2AHTTALDH1A1ROCK2 | |
| SCHEMBL24628685 | 0.82 | DEGS1 (0.54) | MEN1KMT2ANAMPTKDRHTT | |
| SCHEMBL15649419 | 0.81 | RAB9A (0.63) | MEN1KMT2AHTTALDH1A1ROCK2 | |
| SCHEMBL11339882 | 0.81 | NPC1 (0.64) | MEN1KMT2ABCAT2NAMPTKDR | |
| SCHEMBL19087072 | 0.81 | BCAT2 (0.63) | MEN1KMT2ABCAT2NAMPTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| EP-3915988-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3284744-B1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED LLC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-8252812-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2411363-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011019651-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MEN1 4259/4885KMT2A 4313/4885BCAT2 3862/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MEN1 4259/4885KMT2A 4313/4885BCAT2 3862/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4259/4885KMT2A 4313/4885BCAT2 3862/4885 |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | MEN1 1449/4885KMT2A 1987/4885BCAT2 2327/4885 |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4369/4885KMT2A 4259/4885BCAT2 3577/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4259/4885KMT2A 4313/4885BCAT2 3862/4885 |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | MEN1 3215/4885KMT2A 3569/4885BCAT2 4054/4885 |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4369/4885KMT2A 4259/4885BCAT2 3577/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 3986/4885KMT2A 4357/4885BCAT2 3684/4885 |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | MEN1 703/4885KMT2A 2409/4885BCAT2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.